These things can be done, but a lot of legacy silo thinking and billing assets will need tobitethedust in favor of regional VistA-enabled frameworks to act as the regional backbone for a fresh start.
Contrast that with the stench of failure in the drug industry, where experimental medicines are more likely to fail than succeed, and pharmaceutical developers like Pfizer have seen their biggest bets bitethedust.